Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome

急性肺损伤和急性呼吸窘迫综合征的治疗

• 批准号: 8844846
• 负责人: BENNETT P DEBOISBLANC
• 金额: $ 6.83万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8844846
• 关键词: Acute; Acute Lung Injury; Adult; Adult Respiratory Distress Syndrome; Caring; Characteristics; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consent Forms; Critical Illness; Edema; Electronics; Eligibility Determination; Enrollment; Ethics; Gender; Hypoxemia; Intensive Care Units; Lung Inflammation; Natural History; Outcome; Pathology; Patients; Pharmaceutical Preparations; Procedures; Protocols documentation; Publications; Research Personnel; Resources; Respiratory distress; Review Committee; Sampling; Syndrome; Teleconferences; Voting; base; data exchange; improved; meetings; member; mortality; patient population; prevent; protocol development

Acute lung injury (ALI) and its more severe form, adult respiratory distress (ARD), is a devastating clinical syndrome of sudden lung inflammation that results in severe edema and hypoxemia and requires care in the intensive care unit. Mortality is between 30-40% in controlled settings. To date, no single drug has proven effective for improving mortality in ALI/ARDS despite many large and small clinical trials. The objective of the Clinical Research Network (ARDSNet) is to develop and conduct clinical research trials to prevent, treat, and improve the outcome of patients with acute lung injury, acute respiratory distress syndrome, and possibly other related critical illnesses.

急性肺损伤（ALI）及其更严重的形式成人呼吸窘迫（ARD）是一种破坏性的临床综合征，由突发性肺部炎症引起严重水肿和低氧血症，需要在重症监护室进行护理。在受控环境中，死亡率在30-40%之间。迄今为止，尽管进行了许多大大小小的临床试验，但没有一种药物被证明对改善急性呼吸窘迫综合征/急性呼吸窘迫综合征的死亡率有效。临床研究网络（ARDSNet）的目标是开发和开展临床研究试验，以预防、治疗和改善急性肺损伤、急性呼吸窘迫综合征以及可能的其他相关危重疾病患者的预后。